For the quarter ending 2025-09-30, ELTX has $28,284K in assets. $24,468K in debts. $20,611K in cash and cash equivalents.
| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 20,611 | 22,088 | ||
| Restricted cash, current | 0 | 0 | ||
| Prepaid expenses and other current assets | 854 | 510 | ||
| Total current assets | 21,465 | 22,598 | ||
| Property and equipment, net | 328 | 377 | ||
| Operating lease, right-of-use assets | 5,019 | 5,253 | ||
| Restricted cash, noncurrent | 702 | 700 | ||
| Other long-term prepaid assets | 770 | 600 | ||
| Total assets | 28,284 | 29,528 | ||
| Accounts payable | 321 | 3,865 | ||
| Accrued expenses | 5,213 | 5,106 | ||
| Deferred research obligation | 0 | 0 | ||
| Operating lease liability, current | 981 | 952 | ||
| Total current liabilities | 6,515 | 9,923 | ||
| Warrant liabilities | 3,877 | 3,821 | ||
| Operating lease liability, noncurrent | 4,356 | 4,613 | ||
| Long-term debt, net of debt discount and debt issuance costs | 9,720 | 9,337 | ||
| Total liabilities | 24,468 | 27,694 | ||
| Common stock, 0.01 par value per share 300,000,000 shares authorized 17,273,107 shares and 11,043,837 shares issued at september30, 2025 and december31, 2024, respectively 17,258,652 and 11,029,382 outstanding as of september30, 2025 and december31, 2024, respectively | 173 | 163 | ||
| Treasury stock, at cost, 14,455 shares outstanding | 150 | 150 | ||
| Additional paid-in capital | 229,778 | 217,762 | ||
| Accumulated other comprehensive loss | -31 | -70 | ||
| Accumulated deficit | -225,954 | -215,871 | ||
| Total stockholders' equity (deficit) | 3,816 | 1,834 | ||
| Total liabilities and stockholders equity (deficit) | 28,284 | 29,528 | ||
Elicio Therapeutics, Inc. (ELTX)
Elicio Therapeutics, Inc. (ELTX)